16R-HETE and 16S-HETE Alter Human Cytochrome P450 1B1 Enzyme Activity Probably Through an Allosteric Mechanism

Overview

Journal Mol Cell Biochem

Publisher Springer

Specialty Biochemistry

Date 2023 Jul 12

PMID 37436655

Authors

Rahmat Hidayat

Sherif M Shoieb

Farag E S Mosa

Khaled Barakat

Dion R Brocks

Fadumo A Isse

Samar H Gerges

Ayman O S El-Kadi

Affiliations

Soon will be listed here.

Abstract

Cytochrome P450 1B1 (CYP1B1) has been widely associated with the development of cardiac pathologies due to its ability to produce cardiotoxic metabolites like midchain hydroxyeicosatetraenoic acids (HETEs) from arachidonic acid (AA) through an allylic oxidation reaction. 16-HETE is a subterminal HETE that is also produced by CYP-mediated AA metabolism. 19-HETE is another subterminal HETE that was found to inhibit CYP1B1 activity, lower midchain HETEs, and have cardioprotective effects. However, the effect of 16-HETE enantiomers on CYP1B1 has not yet been investigated. We hypothesized that 16(R/S)-HETE could alter the activity of CYP1B1 and other CYP enzymes. Therefore, this study was carried out to investigate the modulatory effect of 16-HETE enantiomers on CYP1B1 enzyme activity, and to examine the mechanisms by which they exert these modulatory effects. To investigate whether these effects are specific to CYP1B1, we also investigated 16-HETE modulatory effects on CYP1A2. Our results showed that 16-HETE enantiomers significantly increased CYP1B1 activity in RL-14 cells, recombinant human CYP1B1, and human liver microsomes, as seen by the significant increase in 7-ethoxyresorufin deethylation rate. On the contrary, 16-HETE enantiomers significantly inhibited CYP1A2 catalytic activity mediated by the recombinant human CYP1A2 and human liver microsomes. 16R-HETE showed stronger effects than 16S-HETE. The sigmoidal binding mode of the enzyme kinetics data demonstrated that CYP1B1 activation and CYP1A2 inhibition occurred through allosteric regulation. In conclusion, our study provides the first evidence that 16R-HETE and 16S-HETE increase CYP1B1 catalytic activity through an allosteric mechanism.

Citing Articles

Typical and atypical metabolic characteristics of three iridaceae isoflavone components: and studies.

Gu J, Zhang H, Wang M, Zhou Y, Deng Z, Shi R Front Pharmacol. 2025; 16:1522857.

PMID: 40008132 PMC: 11850249. DOI: 10.3389/fphar.2025.1522857.

The profile of oxidative stress markers (arachidonic and linoleic acid derivatives) in patients with benign prostatic hyperplasia in relation to metabolic syndrome.

Ratajczak W, Walczakiewicz K, Laszczynska M, Chmielowiec K, Palma J, Drozd A Aging (Albany NY). 2025; 17(1):116-130.

PMID: 39773533 PMC: 11810064. DOI: 10.18632/aging.206187.

11-Hydroxyeicosatetraenoics induces cellular hypertrophy in an enantioselective manner.

Helal S, El-Sherbeni A, El-Kadi A Front Pharmacol. 2024; 15:1438567.

PMID: 39188949 PMC: 11345585. DOI: 10.3389/fphar.2024.1438567.

References

Esteves F, Rueff J, Kranendonk M . The Central Role of Cytochrome P450 in Xenobiotic Metabolism-A Brief Review on a Fascinating Enzyme Family. J Xenobiot. 2021; 11(3):94-114. PMC: 8293344. DOI: 10.3390/jox11030007. View

Powell W, Rokach J . Biosynthesis, biological effects, and receptors of hydroxyeicosatetraenoic acids (HETEs) and oxoeicosatetraenoic acids (oxo-ETEs) derived from arachidonic acid. Biochim Biophys Acta. 2014; 1851(4):340-55. PMC: 5710736. DOI: 10.1016/j.bbalip.2014.10.008. View

Maayah Z, Althurwi H, Abdelhamid G, Lesyk G, Jurasz P, El-Kadi A . CYP1B1 inhibition attenuates doxorubicin-induced cardiotoxicity through a mid-chain HETEs-dependent mechanism. Pharmacol Res. 2016; 105:28-43. DOI: 10.1016/j.phrs.2015.12.016. View

Maayah Z, Althurwi H, El-Sherbeni A, Abdelhamid G, Siraki A, El-Kadi A . The role of cytochrome P450 1B1 and its associated mid-chain hydroxyeicosatetraenoic acid metabolites in the development of cardiac hypertrophy induced by isoproterenol. Mol Cell Biochem. 2017; 429(1-2):151-165. DOI: 10.1007/s11010-017-2943-y. View

Elshenawy O, Anwar-Mohamed A, El-Kadi A . 20-Hydroxyeicosatetraenoic acid is a potential therapeutic target in cardiovascular diseases. Curr Drug Metab. 2013; 14(6):706-19. DOI: 10.2174/1389200211314060007. View

Nussinov R, Tsai C . The different ways through which specificity works in orthosteric and allosteric drugs. Curr Pharm Des. 2012; 18(9):1311-6. PMC: 7458136. DOI: 10.2174/138161212799436377. View

Laskowski R, Gerick F, Thornton J . The structural basis of allosteric regulation in proteins. FEBS Lett. 2009; 583(11):1692-8. DOI: 10.1016/j.febslet.2009.03.019. View

Iwata S, Ohta T . Molecular basis of allosteric activation of bacterial L-lactate dehydrogenase. J Mol Biol. 1993; 230(1):21-7. DOI: 10.1006/jmbi.1993.1122. View

Yuan Y, Tam M, Simplaceanu V, Ho C . New look at hemoglobin allostery. Chem Rev. 2015; 115(4):1702-24. PMC: 4507747. DOI: 10.1021/cr500495x. View

10.

Takayanagi M, Kurisaki I, Nagaoka M . Non-site-specific allosteric effect of oxygen on human hemoglobin under high oxygen partial pressure. Sci Rep. 2014; 4:4601. PMC: 3978498. DOI: 10.1038/srep04601. View

11.

Kotaka M, Ren J, Lockyer M, Hawkins A, Stammers D . Structures of R- and T-state Escherichia coli aspartokinase III. Mechanisms of the allosteric transition and inhibition by lysine. J Biol Chem. 2006; 281(42):31544-52. DOI: 10.1074/jbc.M605886200. View

12.

Leow J, Chan E . Atypical Michaelis-Menten kinetics in cytochrome P450 enzymes: A focus on substrate inhibition. Biochem Pharmacol. 2019; 169:113615. DOI: 10.1016/j.bcp.2019.08.017. View

13.

Davydov D, Halpert J . Allosteric P450 mechanisms: multiple binding sites, multiple conformers or both?. Expert Opin Drug Metab Toxicol. 2008; 4(12):1523-35. PMC: 2651226. DOI: 10.1517/17425250802500028. View

14.

Polic V, Auclair K . Allosteric Activation of Cytochrome P450 3A4 via Progesterone Bioconjugation. Bioconjug Chem. 2017; 28(4):885-889. DOI: 10.1021/acs.bioconjchem.6b00604. View

15.

Dong L, Yuan C, Orlando B, Malkowski M, Smith W . Fatty Acid Binding to the Allosteric Subunit of Cyclooxygenase-2 Relieves a Tonic Inhibition of the Catalytic Subunit. J Biol Chem. 2016; 291(49):25641-25655. PMC: 5207261. DOI: 10.1074/jbc.M116.757310. View

16.

Maayah Z, Abdelhamid G, El-Kadi A . Development of cellular hypertrophy by 8-hydroxyeicosatetraenoic acid in the human ventricular cardiomyocyte, RL-14 cell line, is implicated by MAPK and NF-κB. Cell Biol Toxicol. 2015; 31(4-5):241-59. DOI: 10.1007/s10565-015-9308-7. View

17.

Maayah Z, El-Kadi A . 5-, 12- and 15-Hydroxyeicosatetraenoic acids induce cellular hypertrophy in the human ventricular cardiomyocyte, RL-14 cell line, through MAPK- and NF-κB-dependent mechanism. Arch Toxicol. 2015; 90(2):359-73. DOI: 10.1007/s00204-014-1419-z. View

18.

Shoieb S, El-Kadi A . Enantiomer of 19-Hydroxyeicosatetraenoic Acid Preferentially Protects Against Angiotensin II-Induced Cardiac Hypertrophy. Drug Metab Dispos. 2018; 46(8):1157-1168. DOI: 10.1124/dmd.118.082073. View

19.

Caligiuri S, Rodriguez-Leyva D, Aukema H, Ravandi A, Weighell W, Guzman R . Dietary Flaxseed Reduces Central Aortic Blood Pressure Without Cardiac Involvement but Through Changes in Plasma Oxylipins. Hypertension. 2016; 68(4):1031-8. DOI: 10.1161/HYPERTENSIONAHA.116.07834. View

20.

Caligiuri S, Aukema H, Ravandi A, Lavallee R, Guzman R, Pierce G . Specific plasma oxylipins increase the odds of cardiovascular and cerebrovascular events in patients with peripheral artery disease. Can J Physiol Pharmacol. 2017; 95(8):961-968. DOI: 10.1139/cjpp-2016-0615. View